BioSpace News Archive

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference,

Twist Bioscience Corporation (Nasdaq: TWST) today announced preclinical data for three of its proprietary antibodies against the S1 protein in SARS-CoV-2, the virus that causes COVID-19.

-- Fiscal 2020 Revenues of $90.1M; Increase of 66% over $54.4M in Fiscal 2019 -- -- Strong Growth in Synthetic Biology, NGS Businesses -- -- Twist Biopharma Established 13 Partnerships, 8 with Milestones and/or Royalties in FY20 -- -- Expect Revenue of $110M to $118M for Fiscal 2021 --

Repare Therapeutics Inc. announced that Lloyd M. Segal, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held November 30 – December 3, 2020.

Deciphera Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, has been named one of the Top Places to Work in Massachusetts in the 13th annual employee-based survey project from The Boston Globe.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attende

In the Phase IIb clinical trial, led by MD Anderson, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338), with robust immune response, well-tolerated safety profile, and no reported serious adverse events

Legend Biotech Corporation, a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced that it has appointed Dr. Li Zhu to Legend Biotech’s Board of Directors.

Theralase® Technologies Inc. announced that the U.S. Food and Drug Administration has granted Theralase® Fast Track Designation for its Phase II Bacillus Calmete Guérin -Unresponsive Non Muscle Invasive Bladder Cancer Carcinoma In Situ clinical study.